Back to top
more

Novartis (NVS)

(Real Time Quote from BATS)

$105.53 USD

105.53
842,490

-0.92 (-0.86%)

Updated Nov 11, 2024 03:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (57 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Allergan Falls as Supreme Court Dismisses Restasis Litigation

by Zacks Equity Research

Allergan's (AGN) key drug, Restasis' prospects hurt as the U.S. Supreme Court upholds the ruling of a lower court, which invalidated certain patents protecting the drug.

Novartis' (NVS) BLA for Ophthalmology Drug Accepted by FDA

by Zacks Equity Research

The FDA accepts Novartis' (NVS) BLA seeking approval for brolucizumab for the treatment of wet AMD.

Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran

by Zacks Equity Research

Alnylam (ALNY) reports complete positive results from the phase III ENVISION study of givosiran for the treatment of acute hepatic porphyria.

Kinjel Shah headshot

Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal

by Kinjel Shah

Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.

Ophthotech Gets Rights to Gene Therapy for BEST Disease

by Zacks Equity Research

Ophthotech (OPHT) obtains development/commercialization rights to AAV gene-therapy program for BEST1-related retinal diseases from Penn and UFRF.

Novartis to Market Rizmoic Through Sandoz, Spins Off Alcon

by Zacks Equity Research

Novartis' (NVS) Sandoz signs an agreement with Japanese company, Shionogi, to commercialize constipation drug in key European markets.

Sweta Jaiswal, FRM headshot

Biotechnology Market on a Tear: 5 ETFs in Spotlight

by Sweta Jaiswal, FRM

Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.

Intercept Reports Additional Positive Data From NASH Study

by Zacks Equity Research

Intercept Pharmaceuticals (ICPT) reports positive additional supportive data from its phase III REGENERATE study of obeticholic acid in patients with liver fibrosis due to NASH.

Mark Vickery headshot

Top Research Reports for McDonald's, Enterprise Products & Charles Schwab

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including McDonald's (MCD), Enterprise Products Partners (EPD) and Charles Schwab (SCHW).

Amgen's (AMGN) Osteoporosis Drug Evenity Gets FDA Approval

by Zacks Equity Research

Amgen (AMGN) gets approval in the United States for osteoporosis drug, Evenity.

Corcept (CORT) Rides High on Cushing's Syndrome Drug Korlym

by Zacks Equity Research

Corcept's (CORT) Cushing's syndrome drug Korlym shows a steady progress. The company's efforts to expand the drug's label also hold promise and bode well for long-term growth.

The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca

Kinjel Shah headshot

Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men

by Kinjel Shah

Pfizer's (PFE) blockbuster breast cancer medicine gets FDA approval to treat men. The approval for the expanded indication is based predominately on real-world data.

Kinjel Shah headshot

Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men

by Kinjel Shah

Pfizer's (PFE) blockbuster breast cancer medicine gets FDA approval to treat men. The approval for the expanded indication is based predominately on real-world data.

Kinjel Shah headshot

Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU

by Kinjel Shah

Novartis (NVS) announces plans to acquire IFM Tre, a subsidiary of IFM Therapeutics focused on anti-inflammatory drugs. Pfizer (PFE) & Teva's (TEVA) drugs get regulatory approvals in EU.

Novartis & Amgen in Legal Dispute Over Migraine Drug Aimovig

by Zacks Equity Research

Novartis (NVS) sues Amgen as the latter issues termination notice for migraine drug.

The Zacks Analyst Blog Highlights: Amazon, 3M, Novartis, Schlumberger and ICICI

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Amazon, 3M, Novartis, Schlumberger and ICICI

Achillion Meets Enrollment Target in Kidney Disease Studies

by Zacks Equity Research

Achillion (ACHN) achieves enrollment target in two mid-stage studies evaluating its lead candidate, ACH-4471 in C3G, a devastating disease affecting the kidney.

Novartis Resubmits BLA to FDA for Biosimilar of Neulasta

by Zacks Equity Research

Novartis' (NVS) generic arm Sandoz resubmits its BLA for the proposed biosimilar of Neulasta.

Mark Vickery headshot

Top Analyst Reports for Amazon, 3M & Novartis

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Amazon (AMZN), 3M (MMM) and Novartis (NVS).

Allergan's AMD Drug Lowers Inflammation in Phase III Study

by Zacks Equity Research

Allergan's (AGN) MAPLE study evaluating a 12-week dose of abicipar pegol demonstrates decreased intraocular inflammation in nAMD patients.

Roche Extends Offer Period for Spark Therapeutics Acquisition

by Zacks Equity Research

Roche (RHHBY) withdraws its Premerger Notification and Report Form in connection with the pending acquisition of Spark Therapeutics.

Novartis Gets Approval for Psoriasis Drug Cosentyx in China

by Zacks Equity Research

Novartis' (NVS) psoriasis drug gets approval in China. The company also signs an agreement to expand its biologics therapy manufacturing capability.

Teva's Anti-CGRP Injection Ajovy Gets Approval in Europe

by Zacks Equity Research

Teva's (TEVA) CGRP injection, Ajovy gets marketing approval in the EU after securing approval in the United States last year.

Novartis (NVS) to Acquire Subsidiary of IFM Therapeutics

by Zacks Equity Research

Novartis (NVS) is set to acquire IFM Tre, a subsidiary of IFM Therapeutics LLC, and strengthen its pipeline of drugs for chronic inflammatory disorders.